Literature DB >> 14872503

Vbeta-restricted T cell adherence to endothelial cells: a mechanism for superantigen-dependent vascular injury.

P A Brogan1, V Shah, N Klein, M J Dillon.   

Abstract

OBJECTIVE: To investigate the potential for endothelial cells to operate as superantigen-presenting cells for T cells and the potential for such an interaction to cause endothelial cell activation and injury.
METHODS: Class II major histocompatibility complex (MHC)-positive human umbilical vein endothelial cells (HUVECs) were cocultured for 4 hours with purified T cells and the superantigens staphylococcal enterotoxin B (SEB) or toxic shock syndrome toxin 1 (TSST-1). After staining with fluorescence-conjugated monoclonal antibodies, flow cytometric analysis was performed on the HUVECs and T cells to examine V(beta)-restricted T cell adherence to the endothelial cell monolayer, V(beta)-restricted T cell activation (CD69 up-regulation), surface expression of endothelial cell activation markers, and generation of endothelial microparticles (EMPs).
RESULTS: Coculture of purified T cells with class II MHC-positive HUVECs and either TSST-1 or SEB resulted in V(beta)-restricted CD69 up-regulation by CD4 and CD8 cells (V(beta)2 activation for TSST-1; V(beta)3, V(beta)5.1, and V(beta)12 activation for SEB). Additionally, there was CD4 and CD8 T cell V(beta)-restricted adherence to the HUVEC monolayer at 4 hours. Expression of intercellular adhesion molecule 1, E-selectin, and vascular cell adhesion molecule 1 was up-regulated on the class II MHC-positive HUVECs following exposure to superantigen in the presence of T cells, and there was increased EMP release from activated HUVECs, which occurred earlier and was of greater magnitude than that observed in response to tumor necrosis factor alpha.
CONCLUSION: Class II MHC-positive endothelial cells operate as competent superantigen-presenting cells for CD4 and CD8 lymphocytes in vitro. Dual signaling between endothelial cells and T cells results in V(beta)-restricted activation and adherence to endothelial monolayers and endothelial cell activation and release of EMPs expressing inducible cell adhesion molecules. It is proposed that this mechanism could account in part for the vascular injury associated with superantigen-mediated diseases including Kawasaki disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14872503     DOI: 10.1002/art.20021

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  15 in total

Review 1.  Immunological profile of peripheral blood lymphocytes and monocytes/macrophages in Kawasaki disease.

Authors:  T Matsubara; T Ichiyama; S Furukawa
Journal:  Clin Exp Immunol       Date:  2005-09       Impact factor: 4.330

2.  Anti-neutrophil cytoplasmic antibodies stimulate release of neutrophil microparticles.

Authors:  Ying Hong; Despina Eleftheriou; Abdullah A K Hussain; Fiona E Price-Kuehne; Caroline O Savage; David Jayne; Mark A Little; Alan D Salama; Nigel J Klein; Paul A Brogan
Journal:  J Am Soc Nephrol       Date:  2011-11-03       Impact factor: 10.121

3.  The functions of endothelial progenitor cells were significantly improved after treatment with intravenous immunoglobulin and aspirin in children with Kawasaki disease.

Authors:  Ming Guo Xu; Li Na Men; Ying Zu; Chun Yu Zhao; Xiang Chun Meng; Tao Wang
Journal:  Pediatr Cardiol       Date:  2011-02-16       Impact factor: 1.655

4.  T cell activation profiles in Kawasaki syndrome.

Authors:  P A Brogan; V Shah; L A Clarke; M J Dillon; N Klein
Journal:  Clin Exp Immunol       Date:  2007-12-06       Impact factor: 4.330

5.  Serum brain natriuretic peptide in children with Kawasaki disease.

Authors:  Yu-Ping Sun; Chao-Ping Wei; Wen-di Wang; Xing-Chang Zheng; Ye-Jun Wang; Shao-Chun Ma; Ying-Jun Xu
Journal:  World J Emerg Med       Date:  2010

6.  Superantigen involvement and susceptibility factors in Kawasaki disease: profiles of TCR Vβ2+ T cells and HLA-DRB1, TNF-α and ITPKC genes among Filipino patients.

Authors:  Magdalena F Natividad; Celia Aurora T Torres-Villanueva; Cynthia P Saloma
Journal:  Int J Mol Epidemiol Genet       Date:  2013-03-18

7.  How T-cell-dependent and -independent challenges access the brain: vascular and neural responses to bacterial lipopolysaccharide and staphylococcal enterotoxin B.

Authors:  Jordi Serrats; Paul E Sawchenko
Journal:  Brain Behav Immun       Date:  2009-06-12       Impact factor: 7.217

8.  Polyclonal expansion of TCR Vbeta 21.3+ CD4+ and CD8+ T cells is a hallmark of Multisystem Inflammatory Syndrome in Children.

Authors:  Kenz Le Gouge; Samira Khaldi-Plassart; Rémi Pescarmona; Thierry Walzer; Encarnita Mariotti-Ferrandiz; Etienne Javouhey; Marion Moreews; Anne-Laure Mathieu; Christophe Malcus; Sophia Djebali; Alicia Bellomo; Olivier Dauwalder; Magali Perret; Marine Villard; Emilie Chopin; Isabelle Rouvet; Francois Vandenesh; Céline Dupieux; Robin Pouyau; Sonia Teyssedre; Margaux Guerder; Tiphaine Louazon; Anne Moulin-Zinsch; Marie Duperril; Hugues Patural; Lisa Giovannini-Chami; Aurélie Portefaix; Behrouz Kassai; Fabienne Venet; Guillaume Monneret; Christine Lombard; Hugues Flodrops; Jean-Marie De Guillebon; Fanny Bajolle; Valérie Launay; Paul Bastard; Shen-Ying Zhang; Valérie Dubois; Olivier Thaunat; Jean-Christophe Richard; Mehdi Mezidi; Omran Allatif; Kahina Saker; Marlène Dreux; Laurent Abel; Jean-Laurent Casanova; Jacqueline Marvel; Sophie Trouillet-Assant; David Klatzmann; Alexandre Belot
Journal:  Sci Immunol       Date:  2021-05-25

9.  Staphylococcal toxic shock syndrome toxin-1 induces the translocation and secretion of high mobility group-1 protein from both activated T cells and monocytes.

Authors:  Shirin Kalyan; Anthony W Chow
Journal:  Mediators Inflamm       Date:  2008-11-04       Impact factor: 4.711

10.  Late multiple organ surge in interferon-regulated target genes characterizes staphylococcal enterotoxin B lethality.

Authors:  Gabriela A Ferreyra; Jason M Elinoff; Cumhur Y Demirkale; Matthew F Starost; Marilyn Buckley; Peter J Munson; Teresa Krakauer; Robert L Danner
Journal:  PLoS One       Date:  2014-02-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.